Plasma leptin and neuropeptide Y concentrations in patients with rheumatoid arthritis treated with infliximab, a TNF-α antagonistReport as inadecuate




Plasma leptin and neuropeptide Y concentrations in patients with rheumatoid arthritis treated with infliximab, a TNF-α antagonist - Download this document for free, or read online. Document in PDF available to download.

Rheumatology International

, Volume 32, Issue 11, pp 3383–3389

First Online: 03 November 2011Received: 08 May 2011Accepted: 18 October 2011

Abstract

TNF-α is one of the key proinflammatory cytokines in pathogenesis of rheumatoid arthritis RA. TNF-α was also found to enhance synthesis of leptin. Leptin is mainly adipocyte-derived hormone controlling appetite and energy expenditure. It acts through inhibition of neuropeptide Y secretion. It is possible that TNF-α-induced leptin secretion contributes to body mass reduction in patients with RA. The study was designed to determine the influence of inactivation of the TNF-α with infliximab on plasma leptin and neuropeptide Y concentrations in patients with RA. Sixteen female patients with RA treated with infliximab and 16 healthy women were investigated. Plasma leptin and neuropeptide Y concentrations were determined before, during and after 1 year management of the patients with infliximab and were compared with body mass index and body fatty and lean mass. There was no difference in plasma leptin concentration between the rheumatoid patients before therapy and the controls 15.6 ± 1.85 and 14.5 ± 2.15 ng-ml, respectively. Neuropeptide Y concentration was higher in the patients than in the controls 54.5 ± 3.96 and 24.8 ± 2.80 pmol-l, respectively. Treatment with infliximab resulted in enhancement in leptin concentration 18.5 ± 2.34 ng-ml and a slight increase in neuropeptide Y concentration 58.7 ± 4.66 pmol-l. Physiological relationship between leptin and body mass was shown in the patients and was not altered during the treatment. There was no significant correlation between the disease activity and plasma leptin or neuropeptide Y concentrations.

KeywordsRheumatoid arthritis Infliximab Leptin Neuropeptide Y Body mass AbbreviationsBMIBody mass index

CRPC-reactive protein

DAS28Diseases activity score 28

DEXADual-energy X-ray Absorptiometry

ESRErythrocyte sedimentation rate

NPYNeuropeptide Y

PLTPlatelet count

RARheumatoid arthritis

TNF-αTumour necrosis factor α

WHRWaist-to-hip ratio

Download fulltext PDF



Author: Magdalena Kopec-Medrek - Anna Kotulska - Malgorzata Widuchowska - Marcin Adamczak - Andrzej Więcek - Eugene J. Kucharz

Source: https://link.springer.com/







Related documents